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Abstract 
Using small RNA sequencing of libraries established from cervical samples and cervical cancer cell lines, we have 
previously reported identification of nine and validation of five putative microRNA species encoded by human 
papillomaviruses (HPV) including five microRNAs encoded by HPV 16. Here we have studied the expression of HPV 
16 encoded microRNAs in cervical samples and in HPV 16 containing cell lines. Different sample matrices were col-
lected for the study: 20 paraffin embedded cervical tissue samples, 16 liquid cytology samples, and 16 cervical cell 
samples from women attending colposcopy due to cervical abnormalities, as well as four HPV 16 containing cell lines. 
Total RNA was extracted, the samples were spiked with small synthetic control RNAs, and the expression of five HPV 
16 encoded microRNAs was assessed by real-time PCR amplification. HPV encoded microRNAs could be frequently 
detected, albeit at high cycle counts. HPV16-miR-H1 was detected in 3.6 %, HPV16-miR-H3 in 23.6 %, HPV16-miR-H5 in 
7.3 %, and HPV16-miR-H6 in 18.2 % of all valid samples. True positive signals for HPV16-miR-H2 could not be detected 
in any of the samples. Viral microRNAs were detected most frequently in paraffin-embedded samples: in one sample 
representing normal squamous epithelium, in one cervical intraepithelial neoplasia (CIN) grade 1, one CIN2, three 
CIN3, two squamous cell carcinoma, three adenocarcinoma in situ, and two adenocarcinoma samples. One liquid 
cytology sample from a patient with CIN3 as well as all four cell lines were positive for HPV16-miR-H3. In all cases HPV 
encoded microRNAs were expressed at low levels.
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Human papillomavirus (HPV) infections are the estab-
lished cause of cervical cancer, and they are implicated in 
other cancers in various anatomical sites of women and 
of men. In cervical cancer screening, as well as in triage 
and follow-up of cervical disease, high-risk (hr) HPV 
testing is gaining a firm foothold as an alternative to or in 
parallel with cytology. In addition to positive HPV DNA 
or mRNA findings, the use of cellular protein markers 
such as p16INK4a (von Knebel et al. 2012) or DNA meth-
ylation markers (Lorincz et al. 2016) have been suggested 
to improve the specificity of patient management.
MicroRNAs (miRNAs) are small, non-coding regula-
tory RNA molecules, which regulate the expression of 
numerous if not most human genes. Many viruses also 
encode their own miRNAs, and particularly DNA viruses 
replicating largely in the nucleus have been suggested to 
encode miRNAs. For example for BK, JC and Merkel pol-
yomaviruses, miRNAs have proven significant in regulat-
ing host immune responses and in the establishment of 
persistent infection (Seo et al. 2008, 2009; Bauman et al. 
2011; Lee et al. 2011). Viruses also modify human miRNA 
expression, and several studies including our own 
have reported modifications due to HPV (Melar-New 
and Laimins 2010; Greco et  al. 2011; Zheng and Wang 
2011), but whether HPV encodes miRNAs of its own 
has remained a controversial issue. Gu et  al. reported a 
computer prediction of miRNAs encoded by cutane-
ous and mucosal HPVs (Gu et al. 2011). We have previ-
ously published identification and validation of putative 
HPV encoded miRNAs (Qian et al. 2013). Our work was 
based on sequencing of small RNA libraries established 
from human tissue samples representing HPV associated 
cervical disease, or from HPV containing cell lines. Bio-
informatic tools were developed (Qian et  al. 2012) and 
altogether nine HPV encoded miRNAs were predicted. 
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Attempts were made to validate five of these, and four 
HPV encoded miRNAs were successfully validated: two 
encoded by HPV 16, one by HPV 38, and one by HPV 68. 
Among the original RNA sequencing results the HPV16-
miR-H1 microRNA had only a few read counts in RNA 
sequencing while HPV16-miR-H2 read counts were 
rather high, and both of these were validated by looped-
primer RT-PCR and in situ hybridization, suggesting that 
sequencing read counts cannot be taken as a direct meas-
ure of microRNA expression (Qian et al. 2013).
In order to study and validate the expression of all five 
putative HPV 16 encoded microRNAs, we subjected a 
set of clinical samples representing HPV associated cer-
vical disease as well as HPV 16 containing cell lines to 
real-time PCR analysis for viral miRNAs. In this work an 
LNA enhanced primer based assay was used because the 
design paradigms of the looped-primer RT-PCR assay 
used in our previous study (Qian et  al. 2013) were not 
compatible with some of the putative miRNA sequences. 
The expression of HPV 16 encoded microRNA was fairly 
common among our sample material, and HPV miRNAs 
were frequently detected in paraffin-embedded samples 
and in cell lines. Based on high PCR cycle counts we 
conclude that the expression levels were altogether low. 
Although human miRNAs are robustly regulated and may 
be of use in the diagnosis and monitoring of HPV posi-
tive patients, the low expression levels of HPV encoded 
miRNAs suggest that they are not suitable biomarkers for 
patient management. However, the frequent detection of 
HPV encoded miRNAs in HPV positive tissue and in cell 
lines suggests that viral microRNA may play a role in the 
regulation of viral replication and pathogenesis.
Methods
Samples
Because no established sample type or experimental pro-
cedures exist, we attempted microRNA detection from 
different sample matrices collected for other HPV stud-
ies, including formalin-fixed paraffin-embedded archived 
samples (FFPE) similar to our previous study (Qian et al. 
2013). Altogether 52 cervical samples were collected 
for the study. Twelve cervical samples were collected 
in Aptima sampling medium (Hologic, Marlborough, 
MA). Four samples were collected in Hybrid Capture 2 
(HC2) specimen transport medium (Qiagen, Gaithers-
burg, MD). Sixteen samples were liquid-based cytologi-
cal samples collected in ThinPrep medium (Hologic). 
Twenty FFPE samples representing different grades of 
HPV associated lesions were collected from the archives 
of the Department of Pathology, Helsinki University Hos-
pital Laboratory, and they had all been used in our pre-
vious validation study except for sample N:o 39 (Qian 
et al. 2013). Aptima samples had been stored at −20  °C 
for ca 12 months, HC2 samples for 2 months, and Thin-
Prep samples for 2  months. RNA preparations of FFPE 
samples originated from a previous study and had been 
stored at −70 °C for ca 2 years. The use of cervical patient 
samples was approved by the Ethical Committee of the 
Helsinki and Uusimaa Hospital District.
Four HPV 16 containing cell lines were included in the 
study as well. HPK IA and HPK II cells were established 
and provided by Dr. Matthias Dürst (German Cancer 
Research Center, Heidelberg, Germany; present address: 
University Clinic Jena, Germany) (Dürst et al. 1987). The 
cells were established by transfection of primary human 
foreskin keratinocytes with HPV 16. CaSki epidermoid 
cervical carcinoma cells and SiHa human cervical tumor 
cells were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). All cells were cul-
tured in DMEM (Sigma-Aldrich Inc., Saint Louis, MO) 
supplemented with 10 % fetal bovine serum and penicil-
lin/streptomycin at 37  °C and 5  % CO2 in a humidified 
incubator.
HPV detection and genotyping in clinical samples
All clinical samples were originally collected for other 
HPV studies, and HPV detection and/or genotyping was 
performed with the methods used in those studies. These 
included the Hybrid Capture 2 (HC2) liquid hybridiza-
tion assay (Qiagen; Virtanen et  al. 2016), the Aptima 
HPV assay (Hologic; Virtanen et al. 2016), the LDR-PCR 
microarray genotyping assay developed in our labora-
tory (Qian et al. 2013; Ritari et al. 2012), GeneXpert HPV 
(Cepheid, Sunnyvale, CA) and the Luminex genotyp-
ing assay (Multimetrix/Mikrogen, Neuried, Germany). 
Of these, the LDR-PCR assay has the highest analytical 
sensitivity.
RNA extraction
Aliquots of clinical samples were processed as follows: 
600-μl aliquots of Aptima samples, 300-μl aliquots of 
HC2 samples and 4-ml aliquots of ThinPrep samples 
were extracted using the miRCURY RNA Isolation Kit—
Cell and Plant (Exiqon A/S, Vedbaek, Denmark) applying 
the preparation protocol for nasal or throat swabs. For 
HC2 and ThinPrep samples the cells were first centri-
fuged down (5  min 12,000g for HC2 and 15  min 2900g 
for ThinPrep), after which the supernatant was removed 
and 600 μl of lysis solution was added. After 5 min incu-
bation at room temperature, 600 μl of 70 % ethanol was 
added and the extraction was carried out according to 
the manufacturer’s purification protocol for total RNA. 
600 μl of 70 % ethanol was added directly to Aptima sam-
ple aliquots without adding lysis solution. Total RNA 
was eluted in 50 μl of elution buffer and stored at −70 °C 
until reverse transcription was performed. From each 
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FFPE sample four 20-μm sections were prepared and 
RNA was isolated using the RecoverAll total RNA isola-
tion kit (Ambion, Austin, TX). Total RNA from cultured 
cells was isolated using the mirVana RNA isolation kit 
(Ambion). RNA concentrations were measured in Nan-
oDrop instrument (Thermo Scientific, Wilmington, DE).
MicroRNA real‑time PCR assays
Array-format microRNA real-time PCR (rtPCR) miRNA 
assays were tailored according to the manufacturer’s 
design parameters (Exiqon) for HPV16-miR-H1, -H2, 
-H3, -H5 and -H6 (Table  1). Manufacturer-established 
assays were used for human endogenous RNU6B small 
nuclear RNA and spiked UniSp6 small RNA (Exiqon). 
The miRCURY LNA Universal RT microRNA PCR assays 
were run according to the instructions by the manu-
facturer (Exiqon). The reverse transcription (RT) reac-
tions contained initially 10 ng of extracted RNA, 2 μl of 
5× reaction buffer (including universal RT primer), 1 μl 
of enzyme mix, 0.5 μl of UniSp6 RNA spike-in template 
(75 amol) and water in a total volume of 10 μl. Later, in an 
attempt to increase the detection rate, a maximal volume 
(6.5 μl) of extracted RNA was used representing a range 
of 15–300 ng total RNA in a RT reaction. According to 
assay protocol, UniSp6 small RNA was added in the RT 
reaction, providing the samples with an internal control 
to confirm technical performance of the RT and rtPCR 
reactions. The RT reactions were incubated at 42  °C for 
1 h followed by 95 °C for 5 min, and the resulting com-
plementary DNAs (cDNAs) were stored at −70 °C unless 
rtPCR was performed the same day. For rtPCR reactions 
the cDNAs were diluted 1:100 in nuclease-free water. The 
diluted template was combined 1:1 with 2× ExiLENT 
SYBR Green master mix, and 10 μl of this reaction mix 
was added to each well. All rtPCR reactions were car-
ried out in triplicates. All assays were run using the ABI 
7500 real-time PCR instrument with 96-well format. In 
rtPCR, initial 10 min denaturation at 95 °C was followed 
by 40 amplification cycles (first seven Aptima samples) of 
10  s at 95  °C and 1  min at 60  °C. For all other samples 
the number of cycles was raised to 60 in order to improve 
sensitivity. The assays were designed such that all miRNA 
assays from any individual sample were performed in 
one run in order to avoid repeated freezing and thawing. 
Non-template controls remained negative for all miRNA 
assays.
Target prediction for HPV16‑miR‑H6
HPV16-miR-H6 was a particularly interesting microRNA 
because it had by far the highest read counts in small 
RNA sequencing in our previous study (Qian et al. 2013). 
We therefore performed target prediction of H6 using the 
TargetScan Custom algorithm (Lewis et al. 2005) (Addi-
tional file 1: Table S1). The list of predicted target genes 
was screened by the DAVID 6.7 annotation tool (Dennis 
et  al. 2003; da Huang et  al. 2009) using default DAVID 
parameters for overrepresented biological themes (Addi-
tional file 2: Table S2).
Results
We studied the expression of HPV encoded microRNA in 
a set of 52 cervical samples and four HPV containing cell 
lines. The clinical samples included 12 Aptima samples, 
four HC2 samples, 16 ThinPrep samples and 20 FFPE 
samples. Altogether 47 samples were hrHPV positive, 
three were hrHPV negative, and the HPV status of one 
sample could not be defined due to lack of sample mate-
rial. One hrHPV positive Aptima sample was interpreted 
as invalid in the miRNA assays and was thus omitted 
from the analysis, resulting in 51 analysed clinical sam-
ples and four cell lines. All valid samples and their HPV 
status are described in Table 2. Histology, when available, 
is given for the actual sample (FFPE samples), or for a 
biopsy taken at the time of HPV sampling (Aptima, HC2, 
ThinPrep).
Human endogenous RNU6B small nuclear RNA and 
spiked UniSp6 were used as internal controls. RNU6B 
was amplified at cycles varying from Ct 20 to Ct 38. In 
five samples where RNU6B was amplified at high cycles, 
variation between the replicates was more than one cycle 
(Table  2). RNU6B was also amplified from all cell lines 
because they are of human origin. Of note, the input RNA 
amount was highly variable among the samples, which 
explains the variable Ct cycles of RNU6B amplification. 
Table 1 HPV 16 encoded miRNA candidates [modified from Qian et al. (2013)]
miRNA name Reference genome Location Annotation Strand Mature sequence
HPV16-miR-H1 NC_001526.2 2635–2716 E1 + AGUGUAUGAGCUUAAUGAUAA
HPV16-miR-H2 FJ610147.1 56-1/7906–7851 LCR − AUGUGUAACCCAAAACGGUUUG
HPV16-miR-H3 NC_001526.2 518–642 LCR + CAACUGAUCUCUACUGUUA
HPV16-miR-H5 NC_001526.2 2471–2556 E1 + GUAAAGCAUAGACCAUUG
HPV16-miR-H6 NC_001526.2 6684–6584 L1 – AUCAACAACAGUAACAAA
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UniSp6 spiked control was relatively uniformly ampli-
fied at cycles 21–27, mostly at Ct 21–22. Amplification of 
internal controls was unsuccessful from one hrHPV posi-
tive Aptima sample, which was thus interpreted as invalid 
and was omitted.
We have previously identified five putative HPV 
16 encoded microRNAs (Qian et  al. 2013), which are 
described in Table  1. HPV16-miR-H1 and HPV16-
miR-H5 map to the positive strand within the E1 ORF, 
HPV16-miR-H2 and HPV16-miR-H3 to opposite strands 
of the LCR regulatory region, and HPV16-miR-H6 to 
the negative strand of the L1 ORF. In order to study the 
expression of putative HPV 16 encoded miRNAs, tai-
lored LNA enhanced primer based assays were used 
because the assay design paradigms of looped-primer 
RT-PCR used in our previous study were not compat-
ible with some candidate miRNA sequences. It is impor-
tant to note that the assays were designed in the present 
work for the first time, and thus no comparison data 
from other studies are available. In the assay design we 
aimed at having similar parameters including Tm for all 
assays, and the assays were designed for mature miRNA 
sequences. In our material of clinical samples and cell 
lines, HPV 16 encoded miRNAs were amplified at high 
cycle counts (Table  2). Because low expression levels 
brought about large variation between replicates in some 
cases, the results were interpreted as follows: If three or 
two replicates gave signals within one amplification cycle, 
the sample was considered true positive for that particu-
lar miRNA (Table  2, italicised values). If signals from 
three or two replicates were obtained but they varied 
more than one cycle, or if a signal was obtained only from 
one replicate, the sample was not considered true posi-
tive, however the number of replicates giving a signal is 
given in Table 2.
HPV16-miR-H1 was detected in HPK IA and CaSki 
cells (3.6  % of all samples). None of the samples were 
interpreted true positive for HPV16-miR-H2, although 
positive signals were obtained from sporadic replicates. 
HPV16-miR-H3 was detected in one liquid cytology sam-
ple from a CIN3 patient, in eight paraffin samples (one 
normal squamous epithelium, one CIN2, two CIN3, two 
adenocarcinoma in  situ, two adenocarcinoma samples), 
and in all four cell lines (23.6  %). HPV16-miR-H5 was 
detected in two CIN3 samples and in the HPK IA and 
HPK II cells (7.3  %). Expression of HPV16-miR-H6 was 
validated in one CIN1, two CIN3, two SCC and one AIS 
case, and in all four cell lines (18.2 %). All samples where 
miRNA expression was found were shown to be HPV 16 
positive (Table 2), and the cell lines are known to contain 
HPV 16. HPV encoded miRNAs were not detected in any 
of the samples which remained negative in hrHPV detec-
tion and genotyping assays. Because of the rather small 
study size and the small number of samples per category, 
the expression levels were not normalized to RNU6B or 
UniSp6.
Discussion
An important function of viral microRNAs is to modify 
viral gene expression, the cellular environment of virus 
replication, and the pathogenesis of viral diseases. Among 
human DNA tumor viruses at least the BK, JC and Mer-
kel polyomaviruses encode miRNAs, which negatively 
regulate viral early gene expression with consequent 
escape from host immune attack and facilitation of viral 
replication (Seo et al. 2008, 2009; Lee et al. 2011). Papillo-
maviruses and polyomaviruses are both double-stranded 
DNA viruses causing persistent or latent infections and 
they share functional and molecular similarities, thus it 
is credible that papillomaviruses encode miRNAs of their 
own. Among the scarce scientific literature on the topic, 
detection of miRNAs encoded by human papillomavi-
ruses has been unsuccessful by standard sequencing (Cai 
et al. 2006; Wang et al. 2014) or next generation sequenc-
ing (Lui et  al. 2007). Computer predictions suggested, 
however, the existence of putative miRNA sequences 
encoded by mucosal and cutaneous HPV types (Gu et al. 
2011). Our own studies have identified several puta-
tive HPV encoded microRNAs by SOLiD sequencing of 
small RNA libraries established from both human tissue 
samples and from HPV containing cell lines (Qian et al. 
2013).
In the present work we report that expression of HPV 
encoded microRNAs in human cervical tissue or cell 
samples or in HPV containing cell lines is not infrequent, 
but amplification at high cycles suggests low expression 
levels of viral miRNAs. Viral miRNAs were found alto-
gether in two normal/CIN1 cases and in eleven samples 
with severe histology (CIN2—carcinoma), suggesting 
that miRNA expression is found more often in high-
grade lesions. Among human samples, the highest rate of 
miRNA signal was found in paraffin-embedded samples, 
confirming proper targeting of the HPV associated lesion 
by biopsy, and suggesting that the RNA extraction proto-
col used for these samples was successful. It also shows 
that microRNA can be successfully extracted and ampli-
fied from archival samples. Among other patient sample 
types, the only true HPV miRNA finding was HPV16-
miR-H3 in a ThinPrep sample from a CIN3 patient. 
The amount of cells is much lower in cervical scrapings 
than in FFPE biopsy samples, which may explain poor 
detection of miRNAs, although RNU6B endogenous 
control was amplified at similar cycles from all sample 
types. Low detection rates may also be due to subopti-
mal extraction procedures for miRNA assay. Further, all 
HPV 16 harboring cell lines were found to express HPV 
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microRNAs. Small RNAs used as controls were rigor-
ously amplified at expected cycles, confirming the qual-
ity of the samples and the technical performance of the 
assay platform. Most of the FFPE samples were used in 
our previous validation study and were found positive 
for HPV16-miR-H1 or HPV16-miR-H2 by the looped-
primer RT-PCR assay (Qian et  al. 2013), but were not 
found positive using the LNA enhanced primer based 
assay in the present study. In the present work an LNA 
enhanced primer based assay was used because the 
design paradigms of the looped-primer RT-PCR assay 
were not compatible with some HPV miRNA sequences 
such as HPV16-miR-H6. Also, RNU6B was amplified at 
much higher cycles in the present study than in our pre-
vious work, suggesting differences in assay performance. 
According to the assay manufacturer, the LNA enhanced 
primer based assays used in the present work are more 
specific and, as suggested by our results, less sensitive 
than the looped-primer assays used in our previous work 
where identification of HPV microRNAs was presented 
(Qian et  al. 2013). However, in our previous report, 
both TaqMan qPCR and in  situ hybridization were suc-
cessfully used to validate HPV16-miR-H1 and HPV16-
miR-H2 expression. Different methods to study miRNA 
expression may typically produce different results, which 
are not always quantitatively comparable, and this com-
plicates the evaluation of miRNA applicability for bio-
marker use. In our previous study, 100-fold differences in 
SOLiD small RNA sequencing data could not be repro-
duced in qPCR assays (Qian et al. 2013), suggesting that 
sequencing read counts cannot be used as a quantitative 
measure of miRNA expression. We further want to point 
out that the microRNA rtPCR assays designed for the 
present work have never been used before and therefore 
suboptimal assay design cannot be fully excluded.
Positive signals were most frequently obtained for 
HPV16-miR-H3, which maps to the positive strand 
within the LCR, and for HPV16-miR-H6 which maps 
to the negative strand of L1. In our previous miRNA 
sequencing study, the highest read counts by far were 
obtained for HPV16-miR-H6. Even low viral microRNA 
levels, however, may be sufficient to regulate viral replica-
tion and the expression of cellular target genes and thus 
have a role in the pathogenesis of viral diseases. Indeed, 
HPV16-miR-H2 has one predicted target sequence in the 
viral genome within the long control region upstream 
from replication origin in the HPV 16 genome (Qian 
et al. 2013).
Interestingly, all HPV 16 containing cell lines were 
found to express several HPV microRNAs, and they all 
expressed HPV16-miR-H3 and HPV16-miR-H6. The 
CaSki and SiHa cell lines have been established from cer-
vical carcinoma tumors, whereas HPK IA and HPK II 
cell lines were originally established by transfecting HPV 
16 DNA into foreskin primary keratinocytes (Dürst et al. 
1987). The immortalized HPK cell lines are known to con-
tain a number of chromosomal aberrations (Backsch et al. 
2011). They represent clonal cell lines and thus every cell 
contains HPV 16, whereas in clinical samples HPV may be 
present in only a small proportion of cells. In our previous 
work, RNA sequencing produced 100-fold read counts 
for HPV16-miR-H6 as compared to other viral miRNAs. 
Target prediction for HPV16-miR-H6 yielded altogether 
459 putative target genes (Additional file  1: Table S1), 
and functional annotation of the target genes revealed 
that most enriched biological process functions were cell 
adhesion and cell junction (Additional File 2: Table S2). 
Similar overrepresented functions were found among the 
predicted targets of human miRNAs which were differen-
tially expressed due to HPV 16 E5 expression in our previ-
ous paper (Greco et  al. 2011). Other potential functions 
among the targets were nuclear lumen, DNA binding, and 
calcium ion binding.
We conclude that the expression of human papilloma-
virus 16 encoded microRNAs was not infrequent but the 
expression levels were low in human cervical tissue and 
cell samples as well as in HPV 16 containing cell lines. 
Altogether microRNAs may have potential in the diagno-
sis, triage and follow-up of cervical disease, but cellular 
miRNAs regulated in HPV associated cervical disease 
hold more promise than viral miRNAs. However, fre-
quent detection of viral miRNA, albeit at low levels, par-
ticularly in cell lines suggests that they may regulate viral 
replication and the expression of cellular target genes and 
thus have a role in the pathogenesis of viral diseases.
Conclusions
Human papillomavirus 16 encoded microRNAs can be 
detected in cervical swabs, paraffin embedded tissue 
samples and in HPV containing cell lines. Because of 
low expression levels HPV encoded miRNAs are not well 
suited for biomarkers, but they may play a role in virus 
replication and in the pathogenesis of HPV associated 
diseases.
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